Efficacy of Chronic Immunotherapy for Myelin Oligodendrocyte Glycoprotein-IgG Disease

Update Item Information
Identifier 20190319_nanos_sciplatform3_02-video
Title Efficacy of Chronic Immunotherapy for Myelin Oligodendrocyte Glycoprotein-IgG Disease
Creator John Chen; Collin McClelland; Eric Eggenberger; Alfonso Lopez Chiriboga; Victoria Pelak; Heather Moss; Aubrey Gilbert; Michael Lee; Marie Acierno; Muhammad Bhatti; Jiraporn Jitprapaikulsan; Gregory Van Stavern; Divyanshu Dubey; Andrew McKeon; Jeffrey Bennett; Sean Pittock; Eoin Flanagan; Ore-ofe Adesina; Shannon Beres; Dean Cestari; Gena Heidary; Byron Lam; Veeral Shah; John Fraser
Affiliation (JC) (ALC) (MB) (JJ) (DD) (AM) (SP) (EF) Mayo Clinic, Rochester, Minnesota; (CM) (ML) University of Minnesota, Minneapolis, Minnesota; (EE) Mayo Clinic, Jacksonville, Florida; (VP) University of Colorado Denver School of Medicine, Aurora, Colorado; (HM) The Stanford University Medical Center, Palo Alto, California; (AG) The Permanente Medical Group, Vallejo, California; (MA) Mayo Clinic, Scottsdale, Arizona; (GV) Washington University in St. Louis School of Medicine, St. Louis, Missouri; (JB) University of Colorado School of Medicine, Aurora, Colorado; (OA) McGovern Medical School at the University of Texas at Houston, Houston, Texas; (SB) Stanford University, Palo Alto, California; (DC) Harvard Medical School, Mass Eye & Ear, Boston, Massachusetts; (GH) Boston Children's Hospital, Boston, Massachusetts; (BL) Bascom Palmer Eye Institute, Miami, Florida; (VS) Texas Children's Hospital/Baylor College of Medicine, Houston, Texas; (JF) Western University, London, Ontario, Canada
Subject Demeylinating Disease; Optic Neuropathy; Neuro-Ophth & Systyemic Disease (eg. MS, MG, Thyroid)
Description Myelin oligodendrocyte glycoprotein autoantibody (MOG-IgG) is a recently established serum biomarker of demyelinating disease that is associated with recurrent CNS attacks. The optimal treatment to lower the risk of or prevent relapses is unknown. The goal of this study was to determine the efficacy of chronic immunotherapy in preventing relapse of MOG-IgG-positive demyelinating events.
Date 2019-03
Language eng
Format video/mp4
Type Image/MovingImage
Source 2019 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS 2019: Scientific Platform III
Collection Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/
Publisher North American Neuro-Ophthalmology Society
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management Copyright 2019. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s6jd9d3b
Setname ehsl_novel_nam
ID 1427559
Reference URL https://collections.lib.utah.edu/ark:/87278/s6jd9d3b
Back to Search Results